From DCAT Value Chain Insights (VCI)
Recipharm, a Swedish contract development and manufacturing organization, and Kancera, a Swedish biotechnology company focused on cancer therapy, have signed a contract for the development and manufacture of Kancera’s pharmaceutical candidate, KAND567, which is being developed for counteracting the onset of autoimmune disorders as well as neuritis and pain in connection with chemotherapy against cancer.
As part of the collaboration, Recipharm will develop the preparation that is required for release of KAND567 from capsules as well as manufacturing the pharmaceutical product. The work will be performed at Recipharm’s development facility in Solna, Sweden.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription